We are feeling grateful! Marie Olsson has joined our Finance and Admin team as Administrative Assistant. She has long experience of administration and stores management, in leading positions. She will help bring further structure and make our daily operations even more effective. See her bio here.

It is with great pleasure that we welcome Siv Jönsson to our team! Siv has been working in the pharmacokinetic, pharmacodynamic and pharmacometric areas in the pharmaceutical industry for a total of 5 years (Kabi Pharmacia, AstraZeneca), as a regulatory assessor at the Swedish Medical Products Agency for 9 years, and spent +10 years in academia as a senior lecturer and researcher dealing with methodological and applied pharmacometric projects. She will retain a part time affiliation as a senior researcher in the Pharmacometrics Research Group, Uppsala University. See her bio here.

Mechanism based pharmacometric analysis can be a powerful tool in the development of biosimilar drugs. Pharmetheus recently supported a client with evaluating the impact of study design and expected product differences on the power to demonstrate PK and PD similarity. Find out more in a recent paper by Ari Brekkan et al. AAPS J. 2019 Jul 8;21(5):85.

We are glad to announce that Ida Netterberg (MIDD consultant) is returning to Pharmetheus after recently defending her PhD thesis at Uppsala University. Ida’s thesis focused on pharmacometric evaluation of biomarkers to improve treatment in oncology. See Ida's bio here.

We are happy to welcome Ola Caster in our growing enabler team. Ola comes most recently from a position as a Senior Researcher at the Uppsala Monitoring Centre, where he worked primarily with methods for adverse effect detection and benefit-risk assessment in the post-marketing setting. He has more than ten years of experience from research in statistics and data science, including a PhD in Computer and Systems Sciences. See Ola's bio here.

The Pharmetheus team has recently been strengthened by our first dedicated Project Coordinator, Marie Karlsson. Marie has long prior experience in monitoring data processing and project management in software development. See Marie's bio here. Welcome!

Come meet us at ACoP in Orlando next week. Drop by our booth to discuss model informed drug development with our experts and leaders. There are still opportunities for free speed consulting, should you want input to your strategic or hands-on work.

This year, during the ACOP Meeting in Orlando, Pharmetheus will offer professional pharmacometric consulting sessions (~30 min), free of charge. Talk to us about Pharmacometrics, PBPK, Regulatory strategy, MIDD strategy, and much more! These sessions are open to everyone and independent of any current or future plans to use our services.

Congratulations to our Advisor and Chairman of the Board, Prof. Mats Karlsson, who has been awarded the BCPT Nordic Prize 2019 for his deeds in the field of pharmacometrics, which has been of great importance for both science and education.

Pharmetheus continues to grow and we are very happy to announce the arrival of two new team members, Ari Brekkan, MIDD consultant, and Antonio Klaric, System administrator. Ari recently defended his PhD thesis at Uppsala University. His work focused on the application and use of pharmacometric models in the development of biological medicinal products. Antonio has experience in a variety

A new talent joined our experienced team! We're excited to announce that Qing Xi, working more recently at the University of Otago, New Zealand, started at Pharmetheus.

Pharmetheus is at PAGE 2019 in Stockholm! We look forward to seeing you at booth no. 19-20.

A warm welcome to Robin Svensson, joining our MIDD consultants team! Robin recently graduated from Uppsala University with an important thesis work on how pharmacometrics can be used to improve decision-making for development and use of drugs against tuberculosis.

Enrica Mezzalana joins us from Exprimo. Enrica has a PhD in Bioengineering and Bioinformatics and has been working for >5years as a pharmacometrician to support model informed drug development both in industry and in consultancy.

Rich was formerly Global Head of Statistics and Chief Statistician for Pfizer Inc. with responsibility for approximately 250 statisticians. In that role he led the quantitative assessment of late stage probabilities of technical and regulatory success through modeling and simulation for late-stage assets compared to industry/therapeutic area benchmarks. He was a long standing member of the cross PhRMA statistics group.